Cargando…

Treatment of Multiple Primary Malignancies With PD-1 Inhibitor Camrelizumab: A Case Report and Brief Literature Review

BACKGROUND: With significant advances in the diagnostic tools and treatment modalities of cancer, the incidence of multiple primary malignancies (MPMs) has increased in the last decades. The therapeutic option changed with the arising of immune checkpoint inhibitors (ICIs), which have improved the s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wan, Yuchen, Wang, Zhixue, Yang, Ning, Liu, Fenye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294358/ https://www.ncbi.nlm.nih.gov/pubmed/35865468 http://dx.doi.org/10.3389/fonc.2022.911961

Ejemplares similares

Significant response of pulmonary sarcomatoid carcinoma with obstructive atelectasis to treatment with the PD-1 inhibitor camrelizumab combined with transbronchial cryoablation: A case report and literature review
por: Nian, Jiayun, et al.
Publicado: (2022)

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review
por: Bai, Jing, et al.
Publicado: (2022)

Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab
por: Ye, Wenling, et al.
Publicado: (2023)

Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer
por: Yan, Xin, et al.
Publicado: (2020)

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
por: Lin, Jieheng, et al.
Publicado: (2021)

Multiple primary malignant neoplasm: Case report and comprehensive literature review
por: Ma, Xue-Yan, et al.
Publicado: (2023)

Case Report: Significant Response to Immune Checkpoint Inhibitor Camrelizumab in a Heavily Pretreated Advanced ER+/HER2− Breast Cancer Patient With High Tumor Mutational Burden
por: Wang, Rong, et al.
Publicado: (2021)

Could Camrelizumab Plus Chemotherapy Improve Clinical Outcomes in Advanced Malignancy? A Systematic Review and Network Meta-Analysis
por: Yang, Chao, et al.
Publicado: (2021)

Case Report: Pulmonary Metastases From Epithelioid Sarcoma in Extremity Favourably Responding to Immunotherapy With Camrelizumab
por: Gong, Tao-Jun, et al.
Publicado: (2021)

A Multiple Primary Malignancy Patient With FANCA Gene Mutation: A Case Report and Literature Review
por: Xia, Qing, et al.
Publicado: (2020)

A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma
por: Yang, Qing, et al.
Publicado: (2023)

Camrelizumab Combined With Gemcitabine and Albumin-Bound Paclitaxel for Neoadjuvant Therapy in the Treatment of Progressive Gallbladder Cancer: A Case Report
por: Wu, Jing, et al.
Publicado: (2022)

A Female With Synchronous Multiple Primary Malignant Tumors in the Esophagogastric Junction, Duodenum and Pancreas: Case Report and Review of the Literature
por: Du, Yongxing, et al.
Publicado: (2022)

Primary renal malignant epithelioid angiomyolipoma with distant metastasis: a case report and literature review
por: Zhang, Jun, et al.
Publicado: (2023)

Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports
por: Jin, Yonglong, et al.
Publicado: (2023)

Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report
por: Zhu, Shu-Guang, et al.
Publicado: (2022)

Camrelizumab plus gemcitabine and oxaliplatin for the treatment of advanced intrahepatic cholangiocarcinoma: a bi-centric observational retrospective study
por: Zhang, Yu-Qing, et al.
Publicado: (2023)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Efficacy and Safety of Camrelizumab Monotherapy and Combination Therapy for Cancers: A Systematic Review and Meta-Analysis
por: Wang, Jiting, et al.
Publicado: (2021)

Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer
por: Huang, Yahan, et al.
Publicado: (2022)

Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature
por: Liang, Xiuju, et al.
Publicado: (2019)

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review
por: Shen, Tian, et al.
Publicado: (2020)

PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review
por: Yin, Na, et al.
Publicado: (2022)

Recurrent Gallbladder Carcinoma With pMMR/MSS Achieved a Complete Response Following Camrelizumab Combined With Apatinib: A Case Report
por: Zhong, Liting, et al.
Publicado: (2022)

Camrelizumab for the treatment of advanced cervical adenocarcinoma: a case report and literature review
por: Zhang, Lei, et al.
Publicado: (2022)

Toxic Epidermal Necrolysis-Like Reaction Following Combination Therapy With Camrelizumab and Apatinib for Advanced Gallbladder Carcinoma
por: Yang, Yonghao, et al.
Publicado: (2021)

Pulmonary blastoma treatment response to anti-PD-1 therapy: a rare case report and literature review
por: Xie, Yalin, et al.
Publicado: (2023)

Case Report: A Durable Response to Camrelizumab and Apatinib Combination Therapy in a Heavily Treated Small Cell Carcinoma of the Ovary, Hypercalcemic Type
por: Li, Guiling, et al.
Publicado: (2022)

Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center
por: Ju, Shuguang, et al.
Publicado: (2022)

Efficacy and safety of transarterial chemoembolization combined with lenvatinib and camrelizumab in patients with BCLC-defined stage C hepatocellular carcinoma
por: Wu, Juan, et al.
Publicado: (2023)

Large Aggressive Angiomyxoma of the Liver: A Case Report and Brief Review of the Literature
por: Sun, Pi-Jiang, et al.
Publicado: (2019)

Small Cell Carcinoma of the Prostate: A Case Report and Brief Review of the Literature
por: Weprin, Samuel, et al.
Publicado: (2017)

Epithelioid inflammatory myofibroblastic sarcoma: a case report and brief literature review
por: Dou, Weidong, et al.
Publicado: (2023)

Isolated Renal Calyceal Urothelial Carcinoma Effectively Treated With PD-1 Inhibitor Alone: A Case Report And Literature Review
por: Li, Shihao, et al.
Publicado: (2022)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
por: Xie, Xiao-Hong, et al.
Publicado: (2023)

Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial
por: Hu, Yue, et al.
Publicado: (2020)

Malignant mediastinal mesothelioma treated with anlotinib: a case report and review of the literature
por: Zhang, Yishi, et al.
Publicado: (2023)

Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review
por: Jin, Xin, et al.
Publicado: (2022)

Camrelizumab—targeting a novel PD-1 epitope to treat hepatocellular carcinoma
por: Rakké, Yannick Sebastiaan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_gntqua1lu7qnligka68kk1actn